Mass spectrometric detection of siRNA in plasma samples for doping control purposes

Analytical and Bioanalytical Chemistry

Volumn 398, Issue 3, 2010, Pages 1305-1312

  Kohler, Maxie ^a   Thomas, Andreas ^a   Walpurgis, Katja ^a   Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Doping; Duplex; Exactive mass spectrometry; Oligonucleotide; Sport

Indexed keywords

ACCURATE MASS; ANTISENSE; ANTISENSE OLIGONUCLEOTIDES; CENTRIFUGAL FILTRATION; CLINICAL STUDY; DOPING; DOPING CONTROL; DUPLEX; EXACTIVE MASS SPECTROMETRY; FLOW-INJECTION ANALYSIS; GENE KNOCK DOWN; LIMIT OF DETECTION; MASS SPECTROMETRIC DETECTION; METABOLIC PATHWAYS; MUSCLE GROWTH; MYOSTATIN; PERFORMANCE ENHANCEMENTS; PLASMA SAMPLES; RIBONUCLEIC ACID; SENSITIVE MASS; SPORT;

ACIDS; CENTRIFUGATION; GENE EXPRESSION; MASS SPECTROMETERS; MASS SPECTROMETRY; PURIFICATION; RNA;

OLIGONUCLEOTIDES;

MYOSTATIN; SMALL INTERFERING RNA;

ADOLESCENT; ADULT; BLOOD; CONFERENCE PAPER; DOPING; FEMALE; GENETICS; HUMAN; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; METHODOLOGY; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY; STANDARD; VALIDATION STUDY;

ADOLESCENT; ADULT; BASE SEQUENCE; DOPING IN SPORTS; FEMALE; HUMANS; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MYOSTATIN; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 77957826107     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-010-4013-0     Document Type: Conference Paper

References (29)

1. KA Whitehead R Langer DG Anderson 2009 Knocking down barriers: advances in siRNA delivery Nat Rev Drug Discov 8 129 138 1:CAS:528:DC%2BD1MXhtFOqt70%3D 10.1038/nrd2742
2. J Kurreck 2009 RNA interference: from basic research to therapeutic applications Angew Chem Int Ed Engl 48 1378 1398 1:CAS:528:DC%2BD1MXisFOrsLY%3D 10.1002/anie.200802092
3. TM Rana 2007 Illuminating the silence: understanding the structure and function of small RNAs Nat Rev Mol Cell Biol 8 23 36 1:CAS:528: DC%2BD28XhtlCjt7bE 10.1038/nrm2085
4. DR Corey 2007 Chemical modification: the key to clinical application of RNA interference? J Clin Invest 117 3615 3622 1:CAS:528:DC%2BD2sXhsVals7bJ 10.1172/JCI33483
5. J Kurreck 2003 Antisense technologies. Improvement through novel chemical modifications Eur J Biochem 270 1628 1644 1:CAS:528:DC%2BD3sXjtl2jtbc%3D 10.1046/j.1432-1033.2003.03555.x
6. R Juliano J Bauman H Kang X Ming 2009 Biological barriers to therapy with antisense and siRNA oligonucleotides Mol Pharm 6 686 695 1:CAS:528: DC%2BD1MXlsF2ht7Y%3D 10.1021/mp900093r
7. JB Bramsen MB Laursen AF Nielsen TB Hansen C Bus N Langkjaer BR Babu T Hojland M Abramov A Van Aerschot, et al. 2009 A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity Nucleic Acids Res 37 2867 2881 1:CAS:528:DC%2BD1MXmtlOgsbo%3D 10.1093/nar/gkp106
8. S Gao F Dagnaes-Hansen EJ Nielsen J Wengel F Besenbacher KA Howard J Kjems 2009 The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice Mol Ther 17 1225 1233 1:CAS:528:DC%2BD1MXltFWkt7o%3D 10.1038/mt.2009.91
9. IS Cho J Kim H Lim do HC Ahn H Kim KB Lee YS Lee 2008 Improved serum stability and biophysical properties of siRNAs following chemical modifications Biotechnol Lett 30 1901 1908 1:CAS:528:DC%2BD1cXhtFCqsrrF 10.1007/s10529-008- 9776-4
10. MA Behlke 2008 Chemical modification of siRNAs for in vivo use Oligonucleotides 18 305 319 1:CAS:528:DC%2BD1cXhsVGhu77N 10.1089/oli.2008.0164
11. D Bumcrot M Manoharan V Koteliansky DW Sah 2006 RNAi therapeutics: a potential new class of pharmaceutical drugs Nat Chem Biol 2 711 719 1:CAS:528:DC%2BD28Xht1SrtLfO 10.1038/nchembio839
12. D Haussecker 2008 The business of RNAi therapeutics Hum Gene Ther 19 451 462 1:CAS:528:DC%2BD1cXmsVGlsr0%3D 10.1089/hum.2008.007
13. M Schuelke KR Wagner LE Stolz C Hubner T Riebel W Komen T Braun JF Tobin SJ Lee 2004 Myostatin mutation associated with gross muscle hypertrophy in a child N Engl J Med 350 2682 2688 1:CAS:528:DC%2BD2cXltFGns7c%3D 10.1056/NEJMoa040933
14. CM Liu Z Yang CW Liu R Wang P Tien R Dale LQ Sun 2008 Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice Gene Ther 15 155 160 10.1038/sj.gt.3303016
15. J Acosta Y Carpio I Borroto O Gonzalez MP Estrada 2005 Myostatin gene silenced by RNAi show a zebrafish giant phenotype J Biotechnol 119 324 331 1:CAS:528:DC%2BD2MXhtVarsLnL 10.1016/j.jbiotec.2005.04.023
16. K Tsuchida 2008 Targeting myostatin for therapies against muscle-wasting disorders Curr Opin Drug Discov Dev 11 487 494 1:CAS:528:DC%2BD1cXosFWmurw%3D
17. TY Huang J Liu X Liang BD Hodges SA McLuckey 2008 Collision-induced dissociation of intact duplex and single-stranded siRNA anions Anal Chem 80 8501 8508 1:CAS:528:DC%2BD1cXht1yitbbN 10.1021/ac801331h
18. U Bahr H Aygun M Karas 2008 Detection and relative quantification of siRNA double strands by MALDI mass spectrometry Anal Chem 80 6280 6285 1:CAS:528:DC%2BD1cXotlOnu7g%3D 10.1021/ac800605z
19. CG Huber MR Buchmeiser 1998 On-line cation exchange for suppression of adduct formation in negative-ion electrospray mass spectrometry of nucleic acids Anal Chem 70 5288 5295 1:CAS:528:DyaK1cXntFegtrg%3D 10.1021/ac980791b
20. Y Zou P Tiller IW Chen M Beverly J Hochman 2008 Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry Rapid Commun Mass Spectrom 22 1871 1881 1:CAS:528:DC%2BD1cXotVygs7c%3D 10.1002/rcm.3561
21. G Zhang J Lin K Srinivasan O Kavetskaia JN Duncan 2007 Strategies for bioanalysis of an oligonucleotide class macromolecule from rat plasma using liquid chromatography-tandem mass spectrometry Anal Chem 79 3416 3424 1:CAS:528:DC%2BD2sXjsFylsrs%3D 10.1021/ac0618674
22. SM McCarthy M Gilar J Gebler 2009 Reversed-phase ion-pair liquid chromatography analysis and purification of small interfering RNA Anal Biochem 390 181 188 1:CAS:528:DC%2BD1MXms1Omsr8%3D 10.1016/j.ab.2009.03.042
23. M Thevis W Schänzer 2007 Current role of LC-MS(/MS) in doping control Anal Bioanal Chem 388 1351 1358 1:CAS:528:DC%2BD2sXnsVeqtr8%3D 10.1007/s00216-007-1131-4
24. M Thevis W Schänzer 2007 Mass spectrometry in sports drug testing: Structure characterization and analytical assays Mass Spectrom Rev 26 79 107 1:CAS:528:DC%2BD2sXht1anurw%3D 10.1002/mas.20107
25. M Greig RH Griffey 1995 Utility of organic bases for improved electrospray mass spectrometry of oligonucleotides Rapid Commun Mass Spectrom 9 97 102 1:CAS:528:DyaK2MXjs1eltL0%3D 10.1002/rcm.1290090121
26. D Andreasen JU Fog W Biggs J Salomon IK Dahslveen A Baker P Mouritzen 2010 Improved microRNA quantification in total RNA from clinical samples Methods 50 S6 S9 1:CAS:528:DC%2BC3cXjtVCns74%3D 10.1016/j.ymeth.2010.01.006
27. K Wang S Zhang B Marzolf P Troisch A Brightman Z Hu LE Hood DJ Galas 2009 Circulating microRNAs, potential biomarkers for drug-induced liver injury Proc Natl Acad Sci USA 106 4402 4407 1:CAS:528:DC%2BD1MXjslyhsL4%3D 10.1073/pnas.0813371106
28. PS Mitchell RK Parkin EM Kroh BR Fritz SK Wyman EL Pogosova-Agadjanyan A Peterson J Noteboom KC O'Briant A Allen, et al. 2008 Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci USA 105 10513 10518 1:CAS:528:DC%2BD1cXpsVCltL0%3D 10.1073/pnas.0804549105
29. Mandel J (1964) The statistical analyses of experimental data. John Wiley & Sons, New York